{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":5,"sponsored":0,"items":[{"id":"n_43k2o65gm7hmzlhkpp4a","seq":12151266,"kind":"article","title":"Roche breast cancer pill cleared by FDA","url":"https://www.biopharmadive.com/news/roche-fda-approve-wilserdly-giredestrant-breast-cancer/874884","published":"2026-11-17T18:15:00Z","seen":"2026-11-17T18:46:38Z","lang":"en","source":{"id":"biopharmadive.com","name":"biopharmadive.com","domain":"biopharmadive.com"},"via":"gdelt-gkg-english","topics":["health","economy"],"authors":["Delilah Alvarado"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"}],"story":"st_vqgh7gupykykgnuj557a","category":"health","category_p":0.77,"sentiment":"positive","tone":0.12,"political":0.36},{"id":"n_6r7qodohps4solr7nnpq","seq":5491462,"kind":"article","title":"Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside","url":"https://www.themarketsdaily.com/2026/10/27/zymeworks-highlights-zw191-ovarian-cancer-responses-roche-deal-upside.html","published":"2026-10-27T23:30:00Z","seen":"2026-10-27T23:31:22Z","lang":"en","source":{"id":"themarketsdaily.com","name":"themarketsdaily.com","domain":"themarketsdaily.com"},"via":"gdelt-gkg-english","topics":["economy","health","science","business"],"authors":["Sarita Garza"],"entities":[{"id":"Q16968498","name":"Zymeworks","type":"org"},{"id":"Q2160232","name":"Roche","type":"org"}],"story":"st_6r7qodohps4solr7nnpq","category":"economy-business","category_p":0.74,"sentiment":"positive","tone":0.27,"political":0.15},{"id":"n_7hrzv367c3isthw6ptmq","seq":5485041,"kind":"article","title":"Mutsaerts responde a Roche: «¿Por qué toda antigua liturgia es un tesoro salvo el rito romano antiguo?» – INFOVATICANA","title_en":"Mutsaerts responds to Roche: 'Why is every ancient liturgy a treasure except the ancient Roman rite?' - INFOVATICANA","url":"https://infovaticana.com/2026/10/27/mutsaerts-responde-roche-rito-romano-antiguo","published":"2026-10-27T23:00:00Z","seen":"2026-10-27T23:14:41Z","lang":"es","country":"ES","source":{"id":"infovaticana.com","name":"infovaticana.com","domain":"infovaticana.com","outlet":{"wikidata":"Q28864202","name":"InfoVaticana","type":"website","country":"ES","designations":["website"]}},"via":"gdelt-gkg-translingual","topics":["economy","education"],"entities":[{"id":"Q2521865","name":"Mutsaerts","type":"person"},{"id":"Q2160232","name":"Roche","type":"person"}],"story":"st_7hrzv367c3isthw6ptmq","category":"arts-culture-entertainment","category_p":0.62,"sentiment":"neutral","tone":0.05,"political":0.1},{"id":"n_i6dl26j4kegcpruj6tla","seq":5046528,"kind":"article","title":"STAT+: Roche gets a lung cancer win with its KRAS drug divarasib","url":"https://www.statnews.com/2026/10/26/roche-kras-drug-divarasib-lung-cancer-treatment-win","summary":"One of the more impressive data sets at this year’s ESMO came from a Roche study of its drug divarasib, which treats lung cancer.","published":"2026-10-26T23:17:13Z","seen":"2026-10-26T23:45:03Z","lang":"en","country":"US","source":{"id":"kite-statnews-com-165bdc","name":"statnews.com","domain":"statnews.com","outlet":{"wikidata":"Q28452506","name":"Stat","type":"website","designations":["business","news website","website"]}},"via":"kite-statnews-com-165bdc","topics":["healthcare","usa","biotech","biotechnology","cancer","clinical trials","pharmaceuticals","stat+"],"authors":["Adam Feuerstein and Andrew Joseph"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"}],"image":"https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_500569539_Editorial_Use_Only-645x645.jpeg","mentions":2,"story":"st_i6dl26j4kegcpruj6tla","category":"health","category_p":0.58,"sentiment":"positive","tone":0.52,"political":0.08},{"id":"n_tuy5tm5o6oyjwgcmmrnq","seq":4117902,"kind":"article","title":"로슈, 소세포폐암 신약에 8억달러 베팅…암젠에 도전","title_en":"Roche bets $800 million on a new small cell lung cancer drug... challenging Amgen","url":"https://www.medipana.com/news/articleView.html?idxno=419993","summary":"스위스 제약사 로슈가 캐나다 바이오기업 자임웍스(Zymeworks)의 차세대 폐암 치료제 후보물질을 도입하며 소세포폐암 치료제 시장 공략에 나섰다. 본격적인 임상 효능 데이터가 확보되기 전 최대 8억1300만달러 규모의 계약을 체결하면서 차세대 면역항암제 선점 경쟁에 뛰어든 모양새다. 23일(현지시간) 외신 및 자임웍스 발표에 따르면 로슈는 자임웍스가 개발 중인 DLL3 표적 삼중특이성 T세포 인게이저(T-cell engager·TCE) \\'ZW209\\'의 글로벌 개발 및 상업화 권리를 확보하는 라이선스 계약을 체결했다. 계약에 따라","published":"2026-10-23T22:39:17Z","seen":"2026-10-23T23:50:01Z","lang":"ko","source":{"id":"kite-cdn-medipana-com-912f9c","name":"cdn.medipana.com","domain":"cdn.medipana.com"},"via":"kite-cdn-medipana-com-912f9c","topics":["medicine","파마시안"],"authors":["최봉선 기자"],"entities":[{"id":"Q2160232","name":"Roche","type":"org"},{"id":"Q470517","name":"Amgen","type":"org"}],"story":"st_tuy5tm5o6oyjwgcmmrnq","category":"economy-business","category_p":0.7,"sentiment":"positive","tone":0.43,"political":0.12}]}